Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-59404
Grau, Thomas; Selchow, Petra; Tigges, Marcel; Burri, Reto; Gitzinger, Marc; Böttger, Erik C; Fussenegger, Martin; Sander, Peter (2012). Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 56(2):1142-1145.
PDF - Registered users only
View at publisher
Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA promoter mutations but not ethA mutations.
0 downloads since deposited on 03 Apr 2012
0 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Institute of Medical Microbiology|
|DDC:||570 Life sciences; biology
610 Medicine & health
|Deposited On:||03 Apr 2012 08:57|
|Last Modified:||06 Dec 2013 06:28|
|Publisher:||American Society for Microbiology (ASM)|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page